论文部分内容阅读
目的比较吉西他滨联合奥沙利铂或5氟尿嘧啶(5-Fu)治疗晚期胰腺癌的临床效果。方法选取2013年1月至2015年1月间在黄石市中心医院治疗的86例晚期胰腺癌患者,按随机数字表法分为奥沙利铂组和氟尿嘧啶组,每组43例。比较两组患者短期疗效、无进展生存时间、总生存时间和不良反应发生率。结果两组患者的近期疗效差异均无统计学意义(均P>0.05)。两组患者无进展生存时间和总生存时间差异均无统计学意义(均P>0.05)。氟尿嘧啶组患者并发症发生率显著高于奥沙利铂组,差异有统计学意义(P<0.05)。结论两种治疗方案均具有较好的临床治疗效果,但吉西他滨联合奥沙利铂的治疗方案不良反应更轻微,具有临床应用价值。
Objective To compare the clinical efficacy of gemcitabine combined with oxaliplatin or 5-Fu in the treatment of advanced pancreatic cancer. Methods Totally 86 patients with advanced pancreatic cancer who were treated in Central Hospital of Huangshi from January 2013 to January 2015 were randomly divided into oxaliplatin group and fluorouracil group, with 43 patients in each group. Short-term efficacy, progression-free survival, overall survival and adverse reactions were compared between the two groups. Results There was no significant difference in the short term efficacy between the two groups (all P> 0.05). There was no significant difference between the two groups in progression-free survival and overall survival (P> 0.05). The incidence of complications in patients in fluorouracil group was significantly higher than that in oxaliplatin group (P <0.05). Conclusion Both treatment regimens have good clinical efficacy, but the side effects of gemcitabine combined with oxaliplatin are less serious and have clinical value.